All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials
TE King Jr, C Albera, WZ Bradford… - American journal of …, 2014 - atsjournals.org
Rationale: FVC has emerged as a standard primary endpoint in clinical trials evaluating
novel therapies for patients with idiopathic pulmonary fibrosis (IPF). However, it has recently …
novel therapies for patients with idiopathic pulmonary fibrosis (IPF). However, it has recently …
All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials
TE King Jr, C Albera, WZ Bradford… - … of respiratory and …, 2014 - pubmed.ncbi.nlm.nih.gov
Rationale FVC has emerged as a standard primary endpoint in clinical trials evaluating
novel therapies for patients with idiopathic pulmonary fibrosis (IPF). However, it has recently …
novel therapies for patients with idiopathic pulmonary fibrosis (IPF). However, it has recently …
[PDF][PDF] All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.
KTE Jr, C Albera, WZ Bradford… - AMERICAN …, 2014 - scholar.archive.org
Objectives: To conduct a comprehensive evaluation of mortality in three phase 3 clinical
trials and evaluate the feasibility of mortality trials in patients with IPF. Methods: The study …
trials and evaluate the feasibility of mortality trials in patients with IPF. Methods: The study …
[引用][C] All-Cause Mortality Rate in Patients with Idiopathic Pulmonary Fibrosis. Implications for the Design and Execution of Clinical Trials
TE King, C Albera, WZ Bradford, U Costabel… - American Journal of …, 2014 - cir.nii.ac.jp
All-Cause Mortality Rate in Patients with Idiopathic Pulmonary Fibrosis. Implications for the
Design and Execution of Clinical Trials | CiNii Research CiNii 国立情報学研究所 学術情報 …
Design and Execution of Clinical Trials | CiNii Research CiNii 国立情報学研究所 学術情報 …
[引用][C] All-Cause Mortality Rate in Patients with Idiopathic Pulmonary Fibrosis: Implications for the Design and Execution of Clinical Trials
TE KING, C ALBERA, WZ BRADFORD… - American journal of …, 2014 - pascal-francis.inist.fr
All-Cause Mortality Rate in Patients with Idiopathic Pulmonary Fibrosis: Implications for the
Design and Execution of Clinical Trials CNRS Inist Pascal-Francis CNRS Pascal and …
Design and Execution of Clinical Trials CNRS Inist Pascal-Francis CNRS Pascal and …
All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.
TE King Jr, C Albera, W Bradford, U Costabel… - … AND CRITICAL CARE …, 2014 - iris.unito.it
RATIONALE: FVC has emerged as a standard primary endpoint in clinical trials evaluating
novel therapies for patients with idiopathic pulmonary fibrosis (IPF). However, it has recently …
novel therapies for patients with idiopathic pulmonary fibrosis (IPF). However, it has recently …
[PDF][PDF] All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.
KTE Jr, C Albera, WZ Bradford, U Costabel… - Am J Respir Crit Care …, 2014 - core.ac.uk
Objectives: To conduct a comprehensive evaluation of mortality in three phase 3 clinical
trials and evaluate the feasibility of mortality trials in patients with IPF. Methods: The study …
trials and evaluate the feasibility of mortality trials in patients with IPF. Methods: The study …
All-Cause Mortality Rate in Patients with Idiopathic Pulmonary Fibrosis: Implications for the Design and Execution of Clinical Trials
TE King Jr, C Albera, WZ Bradford… - American Journal of …, 2014 - search.proquest.com
FVC has emerged as a standard primary endpoint in clinical trials evaluating novel
therapies for patients with idiopathic pulmonary fibrosis (IPF). However, it has recently been …
therapies for patients with idiopathic pulmonary fibrosis (IPF). However, it has recently been …
[PDF][PDF] All-Cause Mortality Rate in Patients with Idiopathic Pulmonary Fibrosis
TE King Jr, C Albera, WZ Bradford… - Am J Respir Crit …, 2014 - researchgate.net
Rationale: FVC has emerged as a standard primary endpoint in clinical trials evaluating
novel therapies for patients with idiopathic pulmonary fibrosis (IPF). However, it has recently …
novel therapies for patients with idiopathic pulmonary fibrosis (IPF). However, it has recently …
All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.
TE King Jr, C Albera, WZ Bradford… - American Journal of …, 2014 - europepmc.org
Objectives To conduct a comprehensive evaluation of mortality in three phase 3 clinical trials
and evaluate the feasibility of mortality trials in patients with IPF. Methods The study …
and evaluate the feasibility of mortality trials in patients with IPF. Methods The study …